Global Nonalcoholic Steatohepatitis (NASH) Market Size, Status and Forecast 2019-2025

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Nonalcoholic Steatohepatitis (NASH) Revenue
• 1.4 Market by Type
  • 1.4.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Obeticholic acid（OCA）
  • 1.4.3 Selonsertib
  • 1.4.4 Emricasan
  • 1.4.5 GR-MD-02
  • 1.4.6 IMM-124E
• 1.5 Market by Application
  • 1.5.1 Global Nonalcoholic Steatohepatitis (NASH) Market Share by Application: 2020 VS 2026
  • 1.5.2 Hospital Pharmacy
  • 1.5.3 Online Provider
  • 1.5.4 Retail Pharmacy
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Global Nonalcoholic Steatohepatitis (NASH) Market Perspective (2015-2026)
• 2.2 Global Nonalcoholic Steatohepatitis (NASH) Growth Trends by Regions
  • 2.2.1 Nonalcoholic Steatohepatitis (NASH) Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Nonalcoholic Steatohepatitis (NASH) Historic Market Share by Regions (2015-2020)
  • 2.2.3 Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Nonalcoholic Steatohepatitis (NASH) Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Nonalcoholic Steatohepatitis (NASH) Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Nonalcoholic Steatohepatitis (NASH) Players by Market Size
  • 3.1.1 Global Top Nonalcoholic Steatohepatitis (NASH) Players by Revenue (2015-2020)
  • 3.1.2 Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Nonalcoholic Steatohepatitis (NASH) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Nonalcoholic Steatohepatitis (NASH) Market Concentration Ratio
  • 3.2.1 Global Nonalcoholic Steatohepatitis (NASH) Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Nonalcoholic Steatohepatitis (NASH) Revenue in 2019
• 3.3 Nonalcoholic Steatohepatitis (NASH) Key Players Head office and Area Served
• 3.4 Key Players Nonalcoholic Steatohepatitis (NASH) Product Solution and Service
• 3.5 Date of Enter into Nonalcoholic Steatohepatitis (NASH) Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global Nonalcoholic Steatohepatitis (NASH) Historic Market Size by Type (2015-2020)
• 4.2 Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

• 5.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)
• 5.2 Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2020)
• 6.2 Nonalcoholic Steatohepatitis (NASH) Key Players in North America (2019-2020)
• 6.3 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)
• 6.4 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2020)
• 7.2 Nonalcoholic Steatohepatitis (NASH) Key Players in Europe (2019-2020)
• 7.3 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)
• 7.4 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)

8 China

• 8.1 China Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2020)
• 8.2 Nonalcoholic Steatohepatitis (NASH) Key Players in China (2019-2020)
• 8.3 China Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)
• 8.4 China Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2020)
• 9.2 Nonalcoholic Steatohepatitis (NASH) Key Players in Japan (2019-2020)
• 9.3 Japan Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)
• 9.4 Japan Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2020)
• 10.2 Nonalcoholic Steatohepatitis (NASH) Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)
• 10.4 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)

11 India

• 11.1 India Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2020)
• 11.2 Nonalcoholic Steatohepatitis (NASH) Key Players in India (2019-2020)
• 11.3 India Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)
• 11.4 India Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2020)
• 12.2 Nonalcoholic Steatohepatitis (NASH) Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)
• 12.4 Central & South America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Tobira Therapeutics
  • 13.1.1 Tobira Therapeutics Company Details
  • 13.1.2 Tobira Therapeutics Business Overview
  • 13.1.3 Tobira Therapeutics Nonalcoholic Steatohepatitis (NASH) Introduction
  • 13.1.4 Tobira Therapeutics Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2015-2020))
  • 13.1.5 Tobira Therapeutics Recent Development
• 13.2 Cadila Healthcare
  • 13.2.1 Cadila Healthcare Company Details
  • 13.2.2 Cadila Healthcare Business Overview
  • 13.2.3 Cadila Healthcare Nonalcoholic Steatohepatitis (NASH) Introduction
  • 13.2.4 Cadila Healthcare Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2015-2020)
  • 13.2.5 Cadila Healthcare Recent Development
• 13.3 Conatus Pharmaceuticals
  • 13.3.1 Conatus Pharmaceuticals Company Details
  • 13.3.2 Conatus Pharmaceuticals Business Overview
  • 13.3.3 Conatus Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
  • 13.3.4 Conatus Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2015-2020)
  • 13.3.5 Conatus Pharmaceuticals Recent Development
• 13.4 Galmed Pharmaceuticals
  • 13.4.1 Galmed Pharmaceuticals Company Details
  • 13.4.2 Galmed Pharmaceuticals Business Overview
  • 13.4.3 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
  • 13.4.4 Galmed Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2015-2020)
  • 13.4.5 Galmed Pharmaceuticals Recent Development
• 13.5 Gemphire Therapeutics
  • 13.5.1 Gemphire Therapeutics Company Details
  • 13.5.2 Gemphire Therapeutics Business Overview
  • 13.5.3 Gemphire Therapeutics Nonalcoholic Steatohepatitis (NASH) Introduction
  • 13.5.4 Gemphire Therapeutics Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2015-2020)
  • 13.5.5 Gemphire Therapeutics Recent Development
• 13.6 Genfit
  • 13.6.1 Genfit Company Details
  • 13.6.2 Genfit Business Overview
  • 13.6.3 Genfit Nonalcoholic Steatohepatitis (NASH) Introduction
  • 13.6.4 Genfit Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2015-2020)
  • 13.6.5 Genfit Recent Development
• 13.7 Gilead Sciences
  • 13.7.1 Gilead Sciences Company Details
  • 13.7.2 Gilead Sciences Business Overview
  • 13.7.3 Gilead Sciences Nonalcoholic Steatohepatitis (NASH) Introduction
  • 13.7.4 Gilead Sciences Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2015-2020)
  • 13.7.5 Gilead Sciences Recent Development
• 13.8 Intercept Pharmaceuticals
  • 13.8.1 Intercept Pharmaceuticals Company Details
  • 13.8.2 Intercept Pharmaceuticals Business Overview
  • 13.8.3 Intercept Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
  • 13.8.4 Intercept Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2015-2020)
  • 13.8.5 Intercept Pharmaceuticals Recent Development
• 13.9 Novartis International
  • 13.9.1 Novartis International Company Details
  • 13.9.2 Novartis International Business Overview
  • 13.9.3 Novartis International Nonalcoholic Steatohepatitis (NASH) Introduction
  • 13.9.4 Novartis International Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2015-2020)
  • 13.9.5 Novartis International Recent Development
• 13.10 Takeda
  • 13.10.1 Takeda Company Details
  • 13.10.2 Takeda Business Overview
  • 13.10.3 Takeda Nonalcoholic Steatohepatitis (NASH) Introduction
  • 13.10.4 Takeda Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2015-2020)
  • 13.10.5 Takeda Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer